Candida auris detected in 27 US states, risk groups, symptoms and treatment

The Story in Brief

The US Centers for Disease Control and Prevention (CDC) has reported that the fungus Candida auris has been detected in 27 US states this year, with 3,437 cases identified as of 25 July. That count is about 1,000 fewer than the 4,290 cases reported in the same period last year; California recorded 873 cases, Texas 433 and Tennessee 283, according to ABC citing CDC data. The CDC says the annual number of C. auris cases continues to rise overall but the rate of increase has slowed since 2022, and a rise in reported cases does not necessarily mean the fungus is spreading faster.

Candida auris is a yeast that spreads easily among very ill patients in healthcare facilities. The World Health Organization lists it as a critical‑priority fungal pathogen. It can cause skin infections and serious bloodstream infections by suppressing reactive nitrogen species produced by white blood cells. First described by Korean researchers in 1996 and formally identified as a species in Japan in 2009, C. auris transmits through direct contact with infected or colonised people and via contaminated surfaces and equipment, where it can persist. The CDC analysed 8,033 samples from 2022-23 and found more than 95% resistant to fluconazole, 15% to amphotericin B, about 1% to echinocandins and fewer than 1% resistant to all three drug classes; many strains are resistant to at least one antifungal. According to the CDC, echinocandins remain an effective treatment. People with weakened immunity are at greater risk, while healthy individuals are generally less vulnerable; estimated mortality ranges from 30% to 60% but the CDC notes it is hard to separate the fungus’s contribution to deaths from other pre‑existing illnesses.

The Indian Opinion

The article’s headline and some descriptions label Candida auris as “deadly”, which can sound alarming. The reporting includes facts that temper that impression: most infections are in very ill or immunocompromised patients, the year‑on‑year case count is lower than last year, and the CDC warns that reported rises do not necessarily indicate faster spread. At the same time, the resistance data are concerning and warrant clear public health attention rather than panic. Where the facts are thin – for example, how much C. auris directly causes deaths versus underlying illness – the CDC itself acknowledges uncertainty. An ordinary reader would benefit from balanced emphasis on both the infection risk to vulnerable patients and the ongoing public‑health measures to monitor and treat cases.

Original article: Deadly fungus Candida auris cases detected in 27 US states – Who is at risk, symptoms, treatment (www.livemint.com)

This story was summarised and commented on by AI from the source linked above.